InflaRx (IFRX)

Its lead program is vilobelimab, marketed in the United States under the name GOHIBIC for a specific hospitalized COVID-19-related indication. Vilobelimab is an intravenously administered monoclonal antibody designed to bind free C5a and prevent it from activating inflammatory signaling. The drug candidate has also been studied in other disease settings where complement-driven inflammation may play a role, including severe inflammatory and autoimmune conditions.

InflaRx is also associated with izicopan, a small-molecule C5aR inhibitor candidate that is intended to block signaling through the C5a receptor. The company’s broader platform uses proprietary antibody generation and drug development capabilities to identify potent, specific inhibitors of complement-mediated inflammation.

Based in Europe and listed in the United States, InflaRx operates in the high-risk, research-intensive biotechnology sector. Its value is closely tied to clinical results, regulatory decisions, commercial execution, and the medical relevance of C5a/C5aR inhibition across multiple indications. The company is distinctive for concentrating on a targeted immune pathway rather than pursuing broad immunosuppression, positioning it within the growing field of precision anti-inflammatory medicines.